Sandbox ID Skin and Soft Tissues: Difference between revisions

VisualWikitext

Latest revision as of 16:25, 17 August 2015

Acne vulgaris

Acne vulgaris^[1]

Earliest form, no inflammation

Preferred regimen: Tretinoin (cream 0.025 or 0.05%) Topical qd OR (gel 0.01 or 0.025%) qd
Alternative regimen (1): Adapalene 0.1 % gel Topical qd
Alternative regimen (2): Azelaic acid 20% cream Topical qd
Alternative regimen (3): Tazarotene 0.1% cream Topical qd
Note: Expect 40–70% decrease in comedones in 12 weeks

Mild inflammation

Preferred regimen: Erythromycin 3% Topical AND Benzoyl peroxide 5% Topical bid
Alternative regimen: Clindamycin 1% gel Topical bid AND Benzoyl peroxide 5% Topical bid

Moderate to severe inflammation

Preferred regimen (1): Erythromycin 3% Topical AND Benzoyl peroxide 5% bid ± oral antibiotic
Preferred regimen (2): Isotretinoin 0.1–1 mg/kg IV qd for 4–5 months for severe widespread nodular cystic lesions that fail oral antibiotic treatment

Alternative regimen (1): Doxycycline 100 mg PO bid

Alternative regimen (2):Minocycline 50 mg PO bid OR Minocycline 1 mg/kg expensive extended release qd
Note: Other alternatives include tetracycline, erythromycin, TMP-SMX, clindamycin

Acne rosacea

Acne rosacea ^[2]

1. Facial erythema

Preferred regimen: Brimonidine gel Topical bid, applied to the affected area

2. Papulopustular rosacea

Preferred regimen (1): Azelaic acid gel Topical bid

Preferred regimen (2): Metronidazole cream Topical qd

Anthrax, cutaneous

1. Cutaneous anthrax^[3]

Preferred regimen (1): Penicillin V 500 mg PO qid for 7–10 days
Preferred regimen (2): Ciprofloxacin 500 mg PO bid

Preferred regimen (3): Levofloxacin 500 mg IV/PO qd for 60 days is recommended for bioterrorism cases because of presumed aerosol exposure

Bacillary angiomatosis

Bacillary angiomatosis^[4]

Preferred regimen (1): Erythromycin 500 mg PO qid for 2 weeks to 2 months

Preferred regimen (2): Doxycycline 100 mg PO bid for 2 weeks to 2 months

1. Management of Treatment Failure^[5]

In immunocompromised patients with relapse, retreatment should be continued for 4--6 months; repeated relapses should be treated indefinitely
Among patients whose Bartonella infections fail to respond to initial treatment, one or more of the second-line regimens should be considered

2. Prevention of Recurrence^[5]

Relapses in bone and skin have been reported and are more common when antibiotics are administered for a shorter time (<3 months)
For an immunocompromised HIV-infected adult experiencing relapse, long-term suppression of infection with doxycycline or a macrolide is recommended as long as the CD4 cell count is <200 cells/mm3

Bite wounds

Bite wounds^[6]

Animal bite

Preferred regimen (1): Amoxicillin-clavulanate 875/125 mg PO bid (some gram-negative rods are resistant; misses MRSA)
Preferred regimen (2): Ampicillin-sulbactam 1.5–3.0 g IV q6–8 h (some gram-negative rods are resistant; misses MRSA)
Preferred regimen (3): Piperacillin-tazobactam 3.37 g IV q6–8 h (misses MRSA)
Preferred regimen (4): Doxycycline 100 mg PO bid OR 100 mg IV q12h (excellent activity against Pasteurella multocida; some streptococci are resistant)
Preferred regimen (5): Penicillin AND Dicloxacillin 500 mg PO
Preferred regimen (6): Trimethoprim-Sulfamethoxazole 160–800 mg PO bid OR 5–10 mg/kg IV q24h of TMP component (good activity against aerobes; poor activity against anaerobes)
Preferred regimen (7): Metronidazole 250–500 mg PO tid OR 500 mg IV q8h (Good activity against anaerobes; no activity against aerobes)
Preferred regimen (8): Clindamycin 300 mg PO tid OR 600 mg IV q6–8h (Good activity against staphylococci, streptococci, and anaerobes; misses P. multocida)
Preferred regimen (9): Cefuroxime 500 mg PO bid OR 1 g IV q12h
Preferred regimen (10): Cefoxitin 1 g IV q6–8h
Preferred regimen (11): Ceftriaxone 1 g IV q12h
Preferred regimen (12): Cefotaxime 1–2 g IV q6–8h
Preferred regimen (13): Ciprofloxacin 500–750 mg PO bid OR 400 mg IV q12h
Preferred regimen (14): Levofloxacin 750 mg PO qdOR 750 mg IV q24h
Preferred regimen (15): Moxifloxacin 400 mg PO qd OR 400 mg IV q24h (monotherapy good for anaerobes also)

Human bite

Preferred regimen (1): Amoxicillin-clavulanate 875/125 mg PO bid (some gram-negative rods are resistant; misses MRSA)
Preferred regimen (2): Ampicillin-sulbactam 1.5–3.0 g IV q6h (some gram-negative rods are resistant; misses MRSA)
Preferred regimen (3): Doxycycline 100 mg PO bid (good activity against eikenella species, staphylococci, and anaerobes; some streptococci are resistant)

Lyme disease, cutaneous

Lyme disease^[6]

1. Adults

Preferred regimen (1): Amoxicillin 500 mg PO tid
Preferred regimen (2): Doxycycline 100 mg PO bid
Preferred regimen (3): Cefuroxime axetil 500 mg PO bid OR 30 mg/kg/day PO bid (maximum, 500 mg/dose)
Preferred regimen (4): Ceftriaxone 2 g IV q24h
Alternative regimen (1): Doxycycline 200 mg PO single dose
Alternative regimen (2): Cefotaxime 2 g IV q8h
Alternative regimen (3): Penicillin G 18–24 MU/day IV q4h

2. Pediatrics

Preferred regimen (1): Amoxicillin 50 mg/kg/day PO tid (maximum, 500 mg/dose)
Preferred regimen (2): For children aged 8 years, 4 mg/kg/day PO bid (maximum, 100 mg/dose)
Note: Doxycycline Not recommended for children aged 8 years.
Preferred regimen (3): Cefuroxime axetil 30 mg/kg/day PO bid (maximum, 500 mg/dose)
Preferred regimen (4): Ceftriaxone 50–75 mg/kg/day IV q24h (maximum, 2 g)
Alternative regimen (1): Doxycycline PO (4 mg/kg in children < 8 years of age)
Alternative regimen (2): Cefotaxime 150–200 mg/kg/day IV q6-8h (maximum, 6 g/day)
Alternative regimen (3): Penicillin G 0.2–0.4 MU/kg/day q4h (not to exceed 18–24 MU/day)

Bubonic plague

Bubonic Plague^[6]

Preferred regimen (1): Streptomycin 15 mg/kg IM q12h

Preferred regimen (2): Doxycycline 100 mg PO bid
Preferred regimen (3): Gentamicin could be substituted for streptomycin

Carbuncle

Carbuncle^[7]

Mild

Preferred treatment: Incision and Drainage

Moderate

Empiric treatment: TMP-SMX OR Doxycycline
Culture directed treatment

MSSA: TMP-SMX
MRSA: Dicloxacillin OR Cephalexin

Severe

Empiric treatment: Vancomycin OR Daptomycin OR Linezolid OR Televancin OR Ceftaroline
Culture directed treatment

MSSA: Nafcillin OR Cefazolin OR Clindamycin
MRSA: Vancomycin OR Daptomycin OR Linezolid OR Televancin OR Ceftaroline

Cat scratch disease

Cat scratch disease^[6]

Cat scratch disease in patients > 45 kg

Preferred regimen: Azithromycin 500 mg PO on day 1 AND 250 mg PO for additional 4 days

Cat scratch disease in patients < 45 kg

Preferred regimen: Azithromycin 10 mg/kg PO on day 1 AND 5 mg/kg PO for 4 more days

Cellulitis

Cellulitis^[6]

Non purulent Cellulitis

Mild (typical cellulitis/erysipelas with no focus of purulence)

Preferred regimen (1): Penicillin VK 500 mg PO bid
Preferred regimen (2): Cephalosporin
Preferred regimen (3): Dicloxacillin
Preferred regimen (4): Clindamycin 600-900 mg IV q6-8h

Moderate (typical cellulitis/erysipelas with systemic signs of infection)

Preferred regimen (1): Penicillin VK 500 mg PO bid
Preferred regimen (2): ceftriaxone 1-2 g q4-8h
Preferred regimen (3): cefazolin
Preferred regimen (4): clindamycin 600-900 mg IV q6-8h

Severe infection

Patients who have failed incision and drainage plus oral antibiotics
Those with systemic signs of infection such as temperature >38°C,
Tachycardia (heart rate >90 beats per minute),
Tachypnea (respiratory rate >24 breaths per minute) or
Abnormal white blood cell count (<12 000 or <400 cells/µL), or
Immunocompromised patients
Preferred regimen: Vancomycin AND piperacillin-tazobactam

Purulent Celluitits

Mild (typical cellulitis/erysipelas with no focus of purulence)

Preferred regimen: Incision and Drainage

Moderate (typical cellulitis/erysipelas with systemic signs of infection)

Incision and Drainage
Empiric regimen : TMP-SMX OR doxycycline
MRSA : TMP-SMX
MSSA : Dicloxacillin OR cephalexin

Severe infection: patients who have failed oral antibiotic regimen or those with systemic signs of infection (as defined above under purulent infection), or those who are immunocompromised, or those with clinical signs of deeper infection such as bullae, skin sloughing, hypotension, or evidence of organ dysfunction.

Incision and Drainage
Empiric regimen : Vancomycin OR daptomycin OR linezolid OR televancin OR ceftaroline
MRSA : Vancomycin OR daptomycin OR linezolid OR televancin OR ceftaroline

Ecthyma

Methicillin-Susceptible Staphylococcus Aureus

Preferred regimen (1): Dicloxacillin 250 mg PO qid for 7 days.
Preferred regimen (2): Cephalexin 250 mg PO qid for 7 days.

Methicillin-Resistant Staphylococcus Aureus

Preferred regimen (1): Doxycycline 100 mg PO bid
Preferred regimen (2): Clindamycin 600 mg every 8 h IV or 300–450 mg PO qid
Preferred regimen (3): Sulfamethoxazole-trimethoprim 25–40 mg/kg/d in 3 divided doses IV or 25–30 mg/kg/d in 3 divided doses PO

Erysipelas

Erysipelas^[6]

1. Adults

Preferred regimen (1): Penicillin 500 mg PO qid
Preferred regimen (2): Amoxicillin 500 mg PO qid
Preferred regimen (3): Erythromycin 250 mg PO qid
Preferred regimen (4): Ceftriaxone 1 g IV q24h
Preferred regimen (5): Cefazolin 1 to 2 g IV q8h

2. Pediatrics

Preferred regimen (1): Penicillin 25 to 50 mg/kg/day PO tid or qid
Preferred regimen (2): Amoxicillin 25 to 50 mg/kg/day PO tid
Preferred regimen (3): Erythromycin 30 to 50 mg/kg/day PO bid to qid
Preferred regimen (4): Ceftriaxone 50 to 75 mg/kg/day IV q12-24h
Preferred regimen (5): Cefazolin 100 mg/kg/day IV q8h

Erysipeloid

Erysipeloid^[8]

Preferred regimen (1): Penicillin 500 mg qid for 7–10 days

Preferred regimen (2): Amoxicillin 500 mg tid for 7–10 days

Erythrasma

Erythrasma^[9]

Localized infection

Preferred regimen : Clindamycin Topical bid or tid for 7-14 days

Widespread infection

Preferred regimen (1): Clarithromycin 500 mg PO bid for 14 days

Preferred regimen (2): Erythromycin 250 mg PO bid for 14 days

Fournier gangrene

Fournier gangrene^[10]

If caused by streptococcus species or clostridia

Preferred regimen: Penicillin G

Polymicrobial

Preferred regimen: Doripenem OR imipenem OR meropenem

MRSA (methicillin resistant staphylococcus aureus) suspected

Preferred regimen: vancomycin OR daptomycin

Furuncle

Furuncle^[11]

Mild

Preferred regimen: Incision and Drainage

Moderate

Empiric treatment :TMP-SMX OR Doxycycline
Culture directed treatment

MSSA (methicilin susceptible staphylococcus aureus): TMP-SMX
MRSA (methicilin resistant staphylococcus aureus): dicloxacillin OR cephalexin

Severe

Empiric treatment :Vancomycin OR daptomycin OR linezolid OR televancin OR ceftaroline
Culture directed treatment

MSSA (methicilin susceptible staphylococcus aureus): Nafcillin OR cefazolin OR clindamycin
MRSA (methicilin resistant staphylococcus aureus): Vancomycin OR daptomycin OR linezolid OR televancin OR ceftaroline

Gas gangrene

Gas gangrene^[12]

1. Empiric antimicrobial therapy

Preferred regimen (1): Vancomycin 1 g IV q12h AND (Piperacillin-tazobactam 3.375 g q6h

Preferred regimen (2): Vancomycin 1 g IV q12h AND Ampicillin-sulbactam 3 g IV q6h

Preferred regimen (2): Vancomycin 1 g IV q12h AND Carbapenem)

2. Culture directed antimicrobial therapy

2.1 Clostridium perfringens

Preferred regimen: Penicillin G 24 MU/day IV q4-6h AND Clindamycin 900 mg IV q8h
Alternative regimen (1): Erythromycin 1 g IV q6h
Alternative regimen (2): Ceftriaxone 2 g IV q12h

Glanders

Glanders^[6]

Preferred regimen: Ceftazidime OR Gentamicin OR Imipenem OR Doxycycline OR Ciprofloxacin is recommended based on in vitro susceptibility

Mastitis

Mastitis^[6]

Preferred regimen (1): Amoxicillin-clavulanate 875 mg PO bid
Preferred regimen (2): Cephalexin 500 mg PO qid
Preferred regimen (3): Ciprofloxacin 500 mg PO bid
Preferred regimen (4): Clindamycin 300 mg PO qid
Preferred regimen (5): Dicloxacillin 500 mg PO qid
Preferred regimen (6): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO bid

Necrotizing fasciitis

Necrotizing fasciitis^[6]

1. Mixed infections

1.1 Adults

Preferred regimen (1): Piperacillin-tazobactam 3.37 g IV q6–8h AND Vancomycin 30 mg/kg/day IV q12h
Note: In case of severe pencillin allergy, use clindamycin or metronidazole with an aminoglycoside or fluoroquinolone
Preferred regimen (2): Imipenem-cilastatin 1 g IV q6–8h
Preferred regimen (3): Meropenem 1 g IV q8h
Preferred regimen (4): Ertapenem 1 g IV q24h
Preferred regimen (5): Cefotaxime 2 g IV q6h AND Metronidazole 500 mg IV q6h
Preferred regimen (6): Cefotaxime 2 g IV q6h AND Clindamycin 600–900 mg IV q8h

1.2 Pediatrics

Preferred regimen (1): Piperacillin-tazobactam 60–75 mg/kg/dose of the Piperacillin component IV q6h AND Vancomycin 10–13 mg/kg/dose IV q8h
Note: Severe pencillin allergy, use clindamycin or metronidazole with an aminoglycoside or fluoroquinolone)
Preferred regimen (2): Meropenem 20 mg/kg/dose IV q8h
Preferred regimen (3): Ertapenem 15 mg/kg/dose IV q12h for children 3 months-12 years
Preferred regimen (4): Cefotaxime 50 mg/kg/dose IV q6h AND Metronidazole 7.5 mg/kg/dose IV q6h
Preferred regimen (5): Cefotaxime 50 mg/kg/dose IV q6h AND Clindamycin 10–13 mg/kg/dose IV q8h

2. Streptococcus infection

2.1 Adults

Preferred regimen: Penicillin 2–4 MU IV q4–6h AND Clindamycin 600–900 mg IV q8h
Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin

2.2 Pediatric

Preferred regimen: Penicillin 0.06–0.1 MU/kg/dose IV q6h AND Clindamycin 10–13 mg/kg/dose IV q8h
Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin

3. Staphylococcus aureus

3.1 Adults

Preferred regimen (1): Nafcillin 1–2 g IV q4h
Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
Preferred regimen (2): Oxacillin 1–2 g IV q4h
Preferred regimen (3): Cefazolin 1 g IV q8h
Preferred regimen (4): Vancomycin 30 mg/kg/day IV q12h
Preferred regimen (5): Clindamycin 600–900 mg IV q8h

Pediatrics

Preferred regimen (1): Nafcillin 50 mg/kg/dose IV q6h
Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
Preferred regimen (2): Oxacillin 50 mg/kg/dose IV q6h
Preferred regimen (3): Cefazolin 33 mg/kg/dose IV q8h
Preferred regimen (4): Vancomycin 15 mg/kg/dose IV q6h
Preferred regimen (5): Clindamycin 10–13 mg/kg/dose IV q8h (bacteriostatic; potential cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in MRSA)

4. Clostridium species

4.1 Adults

Preferred regimen: Clindamycin 600–900 mg IV q8h AND Penicillin 2–4 MU IV q4–6h

4.2 Pediatrics

Preferred regimen: Clindamycin 10–13 mg/kg/dose IV q8h AND Penicillin 0.06-0.1 MU/kg/dose IV q6h

5. Aeromonas hydrophila

5.1 Adults

Preferred regimen (1): Doxycycline 100 mg IV q12h AND ciprofloxacin 500 mg IV q12h

Preferred regimen (2): Doxycycline 100 mg IV q12h AND ceftriaxone 1 to 2 g IV q24h

5.2 Pediatrics

Not recommended for children but may need to use in life-threatening situations

6. Vibrio vulnificus

6.1 Adults

Preferred regimen (1): Doxycycline 100 mg IV q12h AND ceftriaxone 1 g IV qid
Preferred regimen (2): Doxycycline 100 mg IV q12h AND cefotaxime 2 g IV tid

6.2 Pediatrics

Not recommended for children but may need to use in life-threatening situation

Pilonidal cyst

Pilonidal cyst^[6]

Preferred regimen: After the pathogens isolated, a 5-10 day course of antibiotic is prescribed.

Pyomyositis

Pyomyositis^[13]

Preferred regimen (1): Nafcillin
Preferred regimen (2): Oxacillin 2 g IV q4h

Preferred regimen (3): Cefazolin 2 g IV q8h (if MSSA)
Alternate regimen: Vancomycin 1 g IV q12h (if MRSA)

Seborrheic dermatitis

Seborrheic dermatitis^[6]

1. Antifungal agents

Preferred regimen (1): Ketoconazole 2% in shampoo, foam, gel, or cream

Scalp: Twice/week for clearance THEN once/week or every other week for maintenance
Other areas: From bid to twice/week for clearance THEN from twice/week to once every other week for maintenance

Preferred regimen (2): Bifonazole 1% in shampoo or cream

Scalp: 3 times/week for clearance
Other areas: qd for clearance

Preferred regimen (3): Ciclopirox olamine (also called ciclopirox) 1.0% or 1.5% in shampoo or cream

Scalp: Twice to 3 times/week for clearance THEN once/week or every 2 week for maintenance
Other areas: Twice daily for clearance THEN qd for maintenance

2. Corticosteroids

Preferred regimen (1): Hydrocortisone 1% in cream areas other than scalp qd or bid
Preferred regimen (2): Betamethasone dipropionate 0.05% in lotion scalp and other areas qd or bid
Preferred regimen (3): Clobetasol 17- butyrate 0.05% in cream areas other than scalp qd or bid
Preferred regimen (4): Clobetasol dipro- pionate 0.05% in shampoo

Scalp: Twice weekly in a short- contact fashion (up to 10 min application, then washing)

Preferred regimen (5): Desonide 0.05% lotion bid on scalp and other areas

3. Lithium salts

Preferred regimen: Lithium succinate AND Zinc sulfate Ointment containing 8% Lithium succinate AND 0.05% Zinc sulfate
Preferred regimen: Lithium gluconate 8% in gel bid on areas other than scalp

Skin and soft tissue infection in neutropenic fever

Treatment of skin and soft tissue infection in neutropenic fever^[6]

1. Initial episode

Empiric treatment : Vancomycin AND (Carbapenem OR Imipenem OR Meropenem OR Doripenem OR Piperacillin-Tazobactam)

2. Recurrent or persistent

Empiric treatment

2.1 Antibacterial therapy

Preferred regimen (1): Vancomycin 30–60 mg/kg/day IV in 2–4 divided doses (Target serum trough concentrations of 15–20 µg/mL in severe infections)
Preferred regimen (2): Daptomycin 4–6 mg/kg/day IV (Covers VRE, strains nonsusceptible to vancomycin may be cross-resistant to daptomycin)
Preferred regimen (3): Linezolid 600 mg q12h IV (100% oral bioavailability; so oral dose same as IV dose. Covers VRE and MRSA)
Preferred regimen (4): Colistin 5 mg/kg IV loaing dose, THEN 2.5 mg/kg q12h IV (Nephrotoxic; does not cover gram-positives or anaerobes, Proteus, Serratia, Burkholderia)

2.2 Antifungal therapy

Preferred regimen (1): Fluconazole 100–400 mg PO q24h OR Fluconazole 800 mg IV loading dose, THEN 400 mg qd (Candida krusei and Candida glabrata are resistant)
Preferred regimen (2): Voriconazole 400 mg PO bid in 2 doses, then 200 mg q12h OR Voriconazole 6 mg/kg IV q12h for 2 doses, THEN 4 mg/kg IV q12h (Accumulation of cyclodextrin vehicle with IV formulation with renal insufficiency)
Preferred regimen (3): Posaconazole 400 mg PO bid with meals (Covers Mucorales)
Preferred regimen (4): Lipid complex Amphotericin-B 5 mg/kg/day IV (Not active against fusaria)
Preferred regimen (5): Liposomal Amphotericin-B 3–5 mg/kg/day IV (Not active against fusaria)

Culture directed antimicrobial therapy

Candida
Aspergillus
Fusarium
Dissemianted HSV or VZV

Skin and soft tissue infection in cellular immunodeficiency

Skin and soft tissue infection in neutropenic fever^[6]
Empiric treatment :

Antibiotics, antifungal, antivirals should be considered in life threatening situtations

Culture directed antimicrobial therapy

Bacteria

Non tuberculosis mycobacteria
Nocardia

Fungus

Aspergillus

Histoplasmosis
Cryptococcus
Candida

Virus

HSV
VZV

Surgical site infection

Surgical site infection treatment^[6]

1. Surgery of intestinal or genitourinary tract

1.1 Single-drug regimens

Preferred regimen (1): Ticarcillin-clavulanate 3.1 g IV q6h
Preferred regimen (2): Piperacillin-tazobactam 3.375 g IV q6h OR Piperacillin-tazobactam 4.5 g IV q8h
Preferred regimen (3): Imipenem-cilastatin 500 mg IV q6h
Preferred regimen (4): Meropenem 1 g IV q8h
Preferred regimen (5): Ertapenem 1 g IV q24h

1.2 Combination regimens

Preferred regimen (1): Ceftriaxone 1 g IV q24h AND metronidazole 500 mg IV q8h
Preferred regimen (2): Ciprofloxacin 400 mg IV q12h (or Ciprofloxacin 750 mg IV PO q12h) AND metronidazole 500 mg IV q8h
Preferred regimen (3): Levofloxacin 750 mg IV q24h AND metronidazole 500 mg IV q8h
Preferred regimen (4): Ampicillin-sulbactam 3 g IV q6h AND gentamicin (OR tobramycin 5 mg/kg IV q24h)

2. Surgery of trunk or extremity away from axilla or perineum

Preferred regimen (1): Oxacillin or nafcillin 2 g IV q6h
Preferred regimen (2): Cefazolin 0.5–1 g IV q8h
Preferred regimen (3): Cephalexin 500 mg PO q6h
Preferred regimen (4): SMX-TMP 160–800 mg PO q6h
Preferred regimen (5): Vancomycin 15 mg/kg IV q12h

3. Surgery of axilla or perineum

Preferred regimen (1): Metronidazole 500 mg IV q8h AND Ciprofloxacin 400 mg IV q12h (OR Ciprofloxacin 750 mg PO q12h)
Preferred regimen (2): Metronidazole 500 mg IV q8h AND Levofloxacin 750 mg IV/PO q24h

Preferred regimen (3): Metronidazole 500 mg IV q8h AND Ceftriaxone 1 g q24h

Tularemia

Tularemia treatment^[6]

Preferred regimen (1): Streptomycin 15 mg/kg IM q12h OR Gentamicin 1.5 mg/kg IV q8h
Preferred regimen (2): Tetracycline 500 mg qid OR doxycycline 100 mg bid PO (for mild cases)

Ulcerated skin: Venous/Arterial Insufficiency; Pressure with Secondary Infection (Infected Decubiti)

Ulcerated skin: venous/arterial insufficiency; pressure with secondary infection (infected decubiti) treatment^[14]

Preferred regimen (1): Imipenem 0.5 g IV q6h (OR Meropenem 1 g IV q24h OR Doripenem 500 mg IV q8h)
Preferred regimen (2): Ticarcillin-Clavulanate 3.1 g IV q8h
Preferred regimen (3): Piperacillin-Tazobactam 3.375 g IV q6h
Preferred regimen (4): Ertapenem 1 g IV q24h
Alternative regimen (1): Ciprofloxacin 500 mg PO bid OR Levofloxacin PO 500 mg qd AND Metronidazole 500 mg PO qid
Alternative regimen (2): Cefepime 2 g IV q12h OR Ceftazidime 2 g IV q8h AND Metronidazole 500 mg PO qid
Note (1): If gram positive cocci on gram stain add Vancomycin.
Note (2): If the ulcer is inflamed, treat with parenteral antibiotics with no topical treatment.
Note (3): If the ulcer is not clinically inflamed, consider debridement, removal of foreign body, reduce the pressure for weight bearing limbs and leg elevation.
Note (4): If not inflamed, healing improved on air bed, protein supplement, radiant heat and electric stimulation.
Note (5): Avoid chlorhexidine and povidone iodine as it may harm the granulation tissue.

Vibrio infection

Vibrio infection^[6]

Vibrio vulnificus in adults

Preferred regimen: Doxycycline 100 mg IV q12h AND ceftriaxone 1 g IV qid OR cefotaxime 2 g IV tid
Note: Antibiotic treatment is not recommended for children but may need to use in life-threatening situation

Wound infection

Wound infection^[15]

1. Mild to moderate

Preferred regimen (1): TMP-SMX-DS double strength 1-2 tabs PO bid
Preferred regimen (2): Clindamycin 300-450 mg PO tid
Alternative regimen (1): Minocycline 100 mg PO bid
Alternative regimen (2): Linezolid 600 mg PO bid

2. Febrile with sepsis

Preferred regimen (1): Ticarcillin-clavulanate 3.1 g IV q4-6h (OR Piperacillin-Tazobactam 3.375 g q6h) AND Vancomycin 1g IV q12h
Preferred regimen (2): Doripenem 500 mg IV q 8hr (OR Imipenem OR Meropenem OR Ertapenem 1g IV q24h) AND Vancomycin 1g IV q12h
Alternative regimen (1): Vancomycin 1 g IV q12h (OR Daptomycin 6 mg/kg IV q24h) AND Ciprofloxacin 750 mg IV q24h (OR Levofloxacin 750 mg IV q24h)
Alternative regimen (2): Ceftaroline 600 mg IV q12h AND Ciprofloxacin 750 mg IV q24h (OR Levofloxacin 750 mg IV q24h)
Alternative regimen (3): Telavancin 10 mg/kg IV q24h AND Ciprofloxacin 750 mg IV q24h (OR Levofloxacin 750 mg IV q24h)

Yaws

Yaws^[6]

Preferred regimen (1): Phenoxymethylpenicillin 12.5 mg/kg q6h 7-10days (maximum dose, 300 mg q6h)
Preferred regimen (2): Tetracyclines 500 mg q6h 15 days or doxycycline 100 mg q12h (alternative agents for the treatment of yaws in nonpregnant adults)
Preferred regimen (3): Erythromycin 8–10 mg/kg 15 days q6h
Preferred regimen (4): Azithromycin 30 mg/kg single-dose (maximum dose 2 g)

References

↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT; et al. (2014). "Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults". Emerg Infect Dis. 20 (2). doi:10.3201/eid2002.130687. PMC 3901462. PMID 24447897.
↑ Spach DH, Koehler JE (1998). "Bartonella-associated infections". Infect Dis Clin North Am. 12 (1): 137–55. PMID 9494835.
↑ ^5.0 ^5.1 Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E; et al. (2009). "Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics". MMWR Recomm Rep. 58 (RR-11): 1–166. PMC 2821196. PMID 19730409.
↑ ^6.00 ^6.01 ^6.02 ^6.03 ^6.04 ^6.05 ^6.06 ^6.07 ^6.08 ^6.09 ^6.10 ^6.11 ^6.12 ^6.13 ^6.14 ^6.15 ^6.16 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Greer N, Foman NA, MacDonald R, Dorrian J, Fitzgerald P, Rutks I; et al. (2013). "Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review". Ann Intern Med. 159 (8): 532–42. doi:10.7326/0003-4819-159-8-201310150-00006. PMID 24126647. Review in: Evid Based Med. 2014 Jun;19(3):91
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[1] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[2] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid24447897-3] Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT; et al. (2014). "Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults". Emerg Infect Dis. 20 (2). doi:10.3201/eid2002.130687. PMC 3901462. PMID 24447897.

[pmid9494835-4] Spach DH, Koehler JE (1998). "Bartonella-associated infections". Infect Dis Clin North Am. 12 (1): 137–55. PMID 9494835.

[pmid19730409-5] 5.0 ^5.1 Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E; et al. (2009). "Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics". MMWR Recomm Rep. 58 (RR-11): 1–166. PMC 2821196. PMID 19730409.

[pmid24947530-6] 6.00 ^6.01 ^6.02 ^6.03 ^6.04 ^6.05 ^6.06 ^6.07 ^6.08 ^6.09 ^6.10 ^6.11 ^6.12 ^6.13 ^6.14 ^6.15 ^6.16 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.

[7] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[8] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[9] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[10] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[11] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[12] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[13] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid24126647-14] Greer N, Foman NA, MacDonald R, Dorrian J, Fitzgerald P, Rutks I; et al. (2013). "Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review". Ann Intern Med. 159 (8): 532–42. doi:10.7326/0003-4819-159-8-201310150-00006. PMID 24126647. Review in: Evid Based Med. 2014 Jun;19(3):91

[15] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

Sandbox ID Skin and Soft Tissues: Difference between revisions

Latest revision as of 16:25, 17 August 2015

Contents

Acne vulgaris

Acne rosacea

Anthrax, cutaneous

Bacillary angiomatosis

Bite wounds

Lyme disease, cutaneous

Bubonic plague

Carbuncle

Cat scratch disease

Cellulitis

Ecthyma

Erysipelas

Erysipeloid

Erythrasma

Fournier gangrene

Furuncle

Gas gangrene

Glanders

Mastitis

Necrotizing fasciitis

Pilonidal cyst

Pyomyositis

Seborrheic dermatitis

Skin and soft tissue infection in neutropenic fever

Skin and soft tissue infection in cellular immunodeficiency

Surgical site infection

Tularemia

Ulcerated skin: Venous/Arterial Insufficiency; Pressure with Secondary Infection (Infected Decubiti)

Vibrio infection

Wound infection

Yaws

References

Navigation menu

@@ Line 129: / Line 129: @@
 ===Cellulitis===
-*Cellulitis<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* Cellulitis<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:*Non purulent :
+:* '''Non purulent Cellulitis'''
-::*Mild : Typical cellulitis/erysipelas with no focus of purulence
+::* '''Mild (typical cellulitis/erysipelas with no focus of purulence)'''
-:::*Preferred treatment : [[Penicillin]] VK 500mg PO bid {{or}} [[cephalosporin]] {{or}} [[dicloxacillin]] {{or}} [[clindamycin]]600-900 mg IV q6-8h
+:::* Preferred regimen (1): [[Penicillin VK]] 500 mg PO bid
-::*Moderate : Typical cellulitis/erysipelas with systemic signs of infection
+:::* Preferred regimen (2): [[Cephalosporin]]
-:::*Preferred treatment : [[Penicillin]] VK 500mg PO bid{{or}} [[ceftriaxone]]1-2 gm q4-8h {{or}} [[cefazolin]] {{or}} [[clindamycin]]600-900 mg IV q6-8h
+:::* Preferred regimen (3): [[Dicloxacillin]]
-::*Severe : patients who have failed incision and drainage plus oral antibiotics or those with systemic signs of infection such as temperature >38°C, tachycardia (heart rate >90 beats per minute), tachypnea (respiratory rate >24 breaths per minute) or abnormal white blood cell count (<12 000 or <400 cells/µL), or immunocompromised patients
+:::* Preferred regimen (4): [[Clindamycin]] 600-900 mg IV q6-8h
-:::*Empiric treatment: [[Vancomycin]] {{and}} [[piperacillin-tazobactam]]
+::* '''Moderate (typical cellulitis/erysipelas with systemic signs of infection)'''
+:::* Preferred regimen (1): [[Penicillin VK]] 500 mg PO bid
-*Purulent :
+:::* Preferred regimen (2): [[ceftriaxone]] 1-2 g q4-8h
-:*Mild : Typical cellulitis/erysipelas with no focus of purulence
+:::* Preferred regimen (3): [[cefazolin]]
-::*Preferred treatment : Incision and Drainage
+:::* Preferred regimen (4): [[clindamycin]] 600-900 mg IV q6-8h
-:*Moderate : Typical cellulitis/erysipelas with systemic signs of infection.
+::* '''Severe infection'''
+:::* Patients who have failed incision and drainage plus oral antibiotics
+:::* Those with systemic signs of infection such as temperature >38°C,
+:::* Tachycardia (heart rate >90 beats per minute),
+:::* Tachypnea (respiratory rate >24 breaths per minute) or
+:::* Abnormal white blood cell count (<12 000 or <400 cells/µL), or
+:::* Immunocompromised patients
+:::* Preferred regimen: [[Vancomycin]] {{and}} [[piperacillin-tazobactam]]
+* '''Purulent Celluitits'''
+:* '''Mild (typical cellulitis/erysipelas with no focus of purulence)'''
+::* Preferred regimen: Incision and Drainage
+:* '''Moderate (typical cellulitis/erysipelas with systemic signs of infection)'''
+::* Incision and Drainage
+::* Empiric regimen : [[TMP-SMX]] {{or}} [[doxycycline]]
+::* MRSA : [[TMP-SMX]]
+::* MSSA : [[Dicloxacillin]] {{or}} [[cephalexin]]
+:*Severe infection: patients who have failed oral antibiotic regimen or those with systemic signs of infection (as defined above under purulent infection), or those who are immunocompromised, or those with clinical signs of deeper infection such as bullae, skin sloughing, hypotension, or evidence of organ dysfunction.
 ::*Incision and Drainage
-::*Empiric treatment : [[TMP-SMX]] {{or}} [[doxycycline]]
+::*Empiric regimen : [[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
-::*MRSA : [[TMP-SMX]]
-::*MSSA : [[Dicloxacillin]] {{or}} [[cephalexin]]
-:*Severe infection: patients who have failed oral antibiotic treatment or those with systemic signs of infection (as defined above under purulent infection), or those who are immunocompromised, or those with clinical signs of deeper infection such as bullae, skin sloughing, hypotension, or evidence of organ dysfunction.
-::*Incision and Drainage
-::*Empiric treatment : [[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
 ::*MRSA : [[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
 ===Ecthyma===
+:*  '''Methicillin-Susceptible Staphylococcus Aureus'''
+::* Preferred regimen (1): [[Dicloxacillin]] 250 mg PO qid for 7 days.
+::* Preferred regimen (2): [[Cephalexin]] 250 mg PO qid for 7 days.
+:*  '''Methicillin-Resistant Staphylococcus Aureus'''
+::* Preferred regimen (1): [[Doxycycline]] 100 mg PO bid
+::* Preferred regimen (2): [[Clindamycin]] 600 mg every 8 h IV or 300–450 mg PO qid
+::* Preferred regimen (3): [[Sulfamethoxazole-trimethoprim]] 25–40 mg/kg/d in 3 divided doses IV or 25–30 mg/kg/d in 3 divided doses PO
 ===Erysipelas===
-*Erysipelas<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* Erysipelas<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:* Erysipelas (Adults)
+:* 1. '''Adults'''
-::* Oral therapy
+::* Preferred regimen (1): [[Penicillin]] 500 mg PO qid
-:::* Preferred regimen (1): [[Penicillin]] 500 mg orally every six hours
+::* Preferred regimen (2): [[Amoxicillin]] 500 mg PO qid
-:::* Preferred regimen (2): [[Amoxicillin]] 500 mg orally every eight hours
+::* Preferred regimen (3): [[Erythromycin]] 250 mg PO qid
-:::* Preferred regimen (3): [[Erythromycin]] 250 mg orally every six hours
+::* Preferred regimen (4): [[Ceftriaxone]] 1 g IV q24h
+::* Preferred regimen (5): [[Cefazolin]] 1 to 2 g IV q8h
-::* Parenteral therapy
+:* 2. '''Pediatrics'''
-:::* Preferred regimen (1): [[Ceftriaxone]] 1g intravenously every 24 hours
+::* Preferred regimen (1): [[Penicillin]] 25 to 50 mg/kg/day PO tid or qid
-:::* Preferred regimen (2): [[Cefazolin]] 1 to 2 g intravenously every eight hours
+::* Preferred regimen (2): [[Amoxicillin]] 25 to 50 mg/kg/day PO tid
+::* Preferred regimen (3): [[Erythromycin]] 30 to 50 mg/kg/day PO bid to qid
+::* Preferred regimen (4): [[Ceftriaxone]] 50 to 75 mg/kg/day IV q12-24h
+::* Preferred regimen (5): [[Cefazolin]] 100 mg/kg/day IV q8h
-:*Erysipelas (pediatrics)
+===Erysipeloid===
-::* Oral therapy
+* Erysipeloid<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:::* Preferred regimen (1): [[Penicillin]] 25 to 50 mg/kg per day orally in three or four doses
+:* Preferred regimen (1): [[Penicillin]] 500 mg qid for 7–10 days
-:::* Preferred regimen (2): [[Amoxicillin]] 25 to 50 mg/kg per day orally in three doses
-:::* Preferred regimen (3): [[Erythromycin]] 30 to 50 mg/kg per day orally in two to four doses
-::*Parenteral therapy
+:* Preferred regimen (2): [[Amoxicillin]] 500 mg tid for 7–10 days
-:::* Preferred regimen (1): [[Ceftriaxone]] 50 to 75 mg/kg per day intravenously in one or two doses
-:::* Preferred regimen (2): [[Cefazolin]] 100 mg/kg per day intravenously in three doses
-===Erysipeloid===
+===Erythrasma===
-*Erysipeloid<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Erythrasma<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Preferred regimen: [[Penicillin]] 500 mg qid for 7–10 days {{or}} [[Amoxicillin]] 500 mg tid for 7–10 days
+:* '''Localized infection'''
+::* Preferred regimen : [[Clindamycin]] Topical bid or tid for 7-14 days
+:* '''Widespread infection'''
+::* Preferred regimen (1): [[Clarithromycin]] 500 mg PO bid for 14 days
-===Erythrasma===
+::* Preferred regimen (2): [[Erythromycin]] 250 mg PO bid for 14 days
-*Erythrasma<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Localized infection
-::* Preferred regimen : Topical [[clindamycin]] 2-3 times daily for 7-14 days
-:* Widespread infection
-::* Preferred regimen : [[clarithromycin]] 500mg PO  bid {{or}} [[erythromycin]] 250mg PO bid for 14 days
 ===Fournier gangrene===
-*Fournier gangrene<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Fournier gangrene<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Streptococcus or clostridia : [[Penicillin]] G
+:* '''If caused by streptococcus species or clostridia'''
-:* Polymicrobial : [[Doripenem]] {{or}} [[imipenem]] {{or}} [[meropenem]]
+::* Preferred regimen: [[Penicillin G]]
-:* MRSA suspected :[[vancomycin]] {{or}} [[daptomycin]]
+:* '''Polymicrobial'''
+::* Preferred regimen: [[Doripenem]] {{or}} [[imipenem]] {{or}} [[meropenem]]
+:* '''MRSA (methicillin resistant staphylococcus aureus) suspected'''
+::* Preferred regimen: [[vancomycin]] {{or}} [[daptomycin]]
 ===Furuncle===
-*Furuncle<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Furuncle<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Mild    : Incision and Drainage
+:* '''Mild'''
-:* Moderate
+::* Preferred regimen: Incision and Drainage
+:* '''Moderate'''
 ::* Empiric treatment :[[TMP-SMX]] {{or}} [[Doxycycline]]
-::*Culture directed treatment
+::* '''Culture directed treatment'''
-:::* MSSA : [[TMP-SMX]]
+:::* MSSA (methicilin susceptible staphylococcus aureus): [[TMP-SMX]]
-:::* MRSA : [[dicloxacillin]] {{or}} [[cephalexin]]
+:::* MRSA (methicilin resistant staphylococcus aureus): [[dicloxacillin]] {{or}} [[cephalexin]]
-:* Severe
+:* '''Severe'''
-::*Empiric treatment :[[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
+::* Empiric treatment :[[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
-::*Culture directed treatment
+::* Culture directed treatment
-:::* MSSA : [[Nafcillin]] {{or}} [[cefazolin]] {{or}} [[clindamycin]]
+:::* MSSA (methicilin susceptible staphylococcus aureus): [[Nafcillin]] {{or}} [[cefazolin]] {{or}} [[clindamycin]]
-:::* MRSA :[[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
+:::* MRSA (methicilin resistant staphylococcus aureus): [[Vancomycin]] {{or}} [[daptomycin]] {{or}} [[linezolid]] {{or}} [[televancin]] {{or}} [[ceftaroline]]
 ===Gas gangrene===
-*Gas gangrene<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Gas gangrene<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Empiric antimicrobial therapy
+:* 1. '''Empiric antimicrobial therapy'''
-::* Preferred regimen : [[vancomycin]]1gm IV q12h {{and}} ([[piperacillin-tazobactam]]3.375 gm q6h {{or}} [[ampicillin-sulbactam]]3 gm IV q6h {{or}} [[carbapenem]])
+::* Preferred regimen (1): [[Vancomycin]] 1 g IV q12h {{and}} ([[Piperacillin-tazobactam]] 3.375 g q6h
-:* Culture directed antimicrobial therapy
-::* Clostridium perfringens
+::* Preferred regimen (2): [[Vancomycin]] 1 g IV q12h {{and}} [[Ampicillin-sulbactam]] 3 g IV q6h
-:::* Preferred regimen   : [[penicillin]] G 24 million units/day divided q4-6h IV {{and}} [[clindamycin]] 900 mg IV q8h
-:::* Alternative regimen : [[erythromycin]]1 gm q6h IV {{or}} [[ceftriaxone]] 2gm IV q12h
+::* Preferred regimen (2): [[Vancomycin]] 1 g IV q12h {{and}} [[Carbapenem]])
+:* 2. '''Culture directed antimicrobial therapy'''
+::* 2.1 '''Clostridium perfringens'''
+:::* Preferred regimen: [[Penicillin G]] 24 MU/day IV q4-6h {{and}} [[Clindamycin]] 900 mg IV q8h
+:::* Alternative regimen (1): [[Erythromycin]] 1 g IV q6h
+:::* Alternative regimen (2): [[Ceftriaxone]] 2 g IV q12h
 ===Glanders===
@@ Line 222: / Line 249: @@
 ===Mastitis===
 *Mastitis<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:*  Preferred regimen (1): [[Amoxicillin]]/[[clavulanate]] (Augmentin), 875 mg twice daily
+:*  Preferred regimen (1): [[Amoxicillin-clavulanate]] 875 mg PO bid
-:*  Preferred regimen (2): [[Cephalexin]] (Keflex),500 mg four times daily
+:*  Preferred regimen (2): [[Cephalexin]] 500 mg PO qid
-:*  Preferred regimen (3): [[Ciprofloxacin]] (Cipro),500 mg twice daily
+:*  Preferred regimen (3): [[Ciprofloxacin]] 500 mg PO bid
-:*  Preferred regimen (4): [[Clindamycin]] (Cleocin),300 mg four times daily
+:*  Preferred regimen (4): [[Clindamycin]] 300 mg PO qid
-:*  Preferred regimen (5): [[Dicloxacillin]] (Dynapen, brand no longer available in the United States), 500 mg four times daily
+:*  Preferred regimen (5): [[Dicloxacillin]] 500 mg PO qid
-:*  Preferred regimen (6): [[Trimethoprim]]/[[sulfamethoxazole]] (Bactrim, Septra),160 mg/800 mg twice daily
+:*  Preferred regimen (6): [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO bid
 ===Necrotizing fasciitis===
 * Necrotizing fasciitis<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:* '''Mixed infections, adult'''
+:* 1. '''Mixed infections'''
-::* Preferred regimen (1): [[Piperacillin-tazobactam]] 3.37 g every 6–8 h IV {{and}} [[vancomycin]] IV 30 mg/kg/d in 2 divided doses (Severe [[Pencillin]] allergy: [[Clindamycin]] or [[metronidazole]] with an [[aminoglycoside]] or [[fluoroquinolone]])
+::* 1.1 '''Adults'''
-::* Preferred regimen (2): [[Imipenem]]-[[cilastatin]] 1 g every 6–8 h IV
+:::* Preferred regimen (1): [[Piperacillin-tazobactam]] 3.37 g IV q6–8h {{and}} [[Vancomycin]] 30 mg/kg/day IV q12h
-::* Preferred regimen (3): [[Meropenem]] 1 g every 8 h IV
+:::* Note: In case of severe pencillin allergy, use clindamycin or metronidazole with an aminoglycoside or fluoroquinolone
-::* Preferred regimen (4): [[Ertapenem]] 1 g daily IV
+:::* Preferred regimen (2): [[Imipenem]]-[[cilastatin]] 1 g IV  q6–8h
-::* Preferred regimen (5): [[Cefotaxime]]2 g every 6 h IV {{and}} ([[metronidazole]]500 mg every 6 h IV {{or}} [[clindamycin]]600–900 mg every 8 h IV)
+:::* Preferred regimen (3): [[Meropenem]] 1 g IV q8h
-:* '''Mixed infections, pediatric'''
+:::* Preferred regimen (4): [[Ertapenem]] 1 g IV q24h
-::* Preferred regimen (1): [[Piperacillin-tazobactam]] 60–75 mg/kg/dose of the [[piperacillin]] component every 6 h IV {{and}} [[vancomycin]] 10–13 mg/kg/dose every 8 h IV (Severe Pencillin allergy: [[Clindamycin]] or [[metronidazole]] with an [[aminoglycoside]] or [[fluoroquinolone]])
+:::* Preferred regimen (5): [[Cefotaxime]] 2 g IV q6h {{and}} [[Metronidazole]] 500 mg IV q6h
-::* Preferred regimen (2): [[Meropenem]] 20 mg/kg/dose every 8 h IV
+:::* Preferred regimen (6): [[Cefotaxime]] 2 g IV q6h {{and}} [[Clindamycin]] 600–900 mg IV q8h
-::* Preferred regimen (3): [[Ertapenem]] 15 mg/kg/dose every 12 h IV for children 3 mo-12 y
+::* 1.2 '''Pediatrics'''
-::* Preferred regimen (4): [[Cefotaxime]]50 mg/kg/dose every 6 h IV{{and}} ([[metronidazole]]7.5 mg/kg/dose every 6 h IV{{or}} [[clindamycin]]10–13 mg/kg/dose every 8 h IV)
+:::* Preferred regimen (1): [[Piperacillin-tazobactam]] 60–75 mg/kg/dose of the [[Piperacillin]] component IV q6h {{and}} [[Vancomycin]] 10–13 mg/kg/dose IV q8h
-:* '''Streptococcus, adult'''
+:::* Note: Severe pencillin allergy, use clindamycin or metronidazole with an aminoglycoside or fluoroquinolone)
-::* Preferred regimen: [[Penicillin]] 2–4 million units every 4–6 h IV (adult) {{and}} [[clindamycin]] 600–900 mg every 8 h IV (Severe Pencillin allergy: [[Vancomycin]], [[linezolid]], [[quinupristin]]/[[dalfopristin]], [[daptomycin]])
+:::* Preferred regimen (2): [[Meropenem]] 20 mg/kg/dose IV q8h
-:* '''Streptococcus, pediatric'''
+:::* Preferred regimen (3): [[Ertapenem]] 15 mg/kg/dose IV q12h for children 3 months-12 years
-::* Preferred regimen: [[Penicillin]]60 000–100 000 units/kg/dose every 6 h IV {{and}} [[clindamycin]] 10–13 mg/kg/dose every 8 h IV (Severe Pencillin allergy: [[Vancomycin]], [[linezolid]], [[quinupristin]]/[[dalfopristin]], [[daptomycin]])
+:::* Preferred regimen (4): [[Cefotaxime]] 50 mg/kg/dose IV q6h {{and}} [[Metronidazole]] 7.5 mg/kg/dose IV q6h
-:* '''Staphylococcus aureus, adult'''
+:::* Preferred regimen (5): [[Cefotaxime]] 50 mg/kg/dose IV q6h {{and}} [[Clindamycin]] 10–13 mg/kg/dose IV q8h
-::* Preferred regimen (1): [[Nafcillin]] 1–2 g every 4 h IV (Severe Pencillin allergy: [[Vancomycin]], [[linezolid]], [[quinupristin]]/[[dalfopristin]], daptomycin)
+:* 2. '''Streptococcus infection'''
-::* Preferred regimen (2): [[Oxacillin]] 1–2 g every 4 h IV
+::* 2.1 '''Adults'''
-::* Preferred regimen (3): [[Cefazolin]] 1 g every 8 h IV
+:::* Preferred regimen: [[Penicillin]] 2–4 MU IV q4–6h {{and}} [[Clindamycin]] 600–900 mg IV q8h
-::* Preferred regimen (4): [[Vancomycin]] 30 mg/kg/d in 2 divided doses IV
+:::* Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
-::* Preferred regimen (5): [[Clindamycin]] 600–900 mg every 8 h IV
+::* 2.2 '''Pediatric'''
-::* '''Staphylococcus aureus, pediatric'''
+:::* Preferred regimen: [[Penicillin]] 0.06–0.1 MU/kg/dose IV q6h {{and}} [[Clindamycin]] 10–13 mg/kg/dose IV q8h
-:::* Preferred regimen (1): [[Nafcillin]] 50 mg/kg/dose every 6 h IV (Severe Pencillin allergy: [[Vancomycin]], [[linezolid]], [[quinupristin]]/[[dalfopristin]], [[daptomycin]])
+:::* Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
-:::* Preferred regimen (2): [[Oxacillin]] 50 mg/kg/dose every 6 h IV
+:* 3. '''Staphylococcus aureus'''
-:::* Preferred regimen (3): [[Cefazolin]] 33 mg/kg/dose every 8 h IV
+::* 3.1 '''Adults'''
-:::* Preferred regimen (4): [[Vancomycin]] 15 mg/kg/dose every 6 h IV
+:::* Preferred regimen (1): [[Nafcillin]] 1–2 g IV q4h
-:::* Preferred regimen (5): [[Clindamycin]] 10–13 mg/kg/dose every 8 h IV ([[Bacteriostatic]]; potential cross-resistance and emergence of resistance in [[erythromycin]]-resistant strains; inducible resistance in MRSA)
+:::* Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
-::*'''Clostridium species, adult'''
+:::* Preferred regimen (2): [[Oxacillin]] 1–2 g IV q4h
-:::*Preferred regimen: [[Clindamycin]] 600–900 mg every 8 h IV {{and}} [[penicillin]] 2–4 million units every 4–6 h IV
+:::* Preferred regimen (3): [[Cefazolin]] 1 g IV q8h
-::*'''Clostridium species, pediatric'''
+:::* Preferred regimen (4): [[Vancomycin]] 30 mg/kg/day IV q12h
-:::*Preferred regimen: [[Clindamycin]] 10–13 mg/kg/dose every 8 h IV {{and}} [[penicillin]] 60 000–100 00 units/kg/dose every 6 h IV
+:::* Preferred regimen (5): [[Clindamycin]] 600–900 mg IV q8h
-::*'''Aeromonas hydrophila, adult'''
+::* '''Pediatrics'''
-::*Preferred regimen: [[Doxycycline]] 100 mg every 12 h IV {{and}} ([[ciprofloxacin]] 500 mg every 12 h IV {{or}} [[ceftriaxone]] 1 to 2 g every 24 h IV)
+:::* Preferred regimen (1): [[Nafcillin]] 50 mg/kg/dose IV q6h
-:*'''Aeromonas hydrophila, pediatric'''
+:::* Note: In case of severe pencillin allergy, use vancomycin, linezolid, quinupristin/dalfopristin, daptomycin
-(Not recommended for children but may need to use in life-threatening situations)
+:::* Preferred regimen (2): [[Oxacillin]] 50 mg/kg/dose IV q6h
-:*'''Vibrio vulnificus, adult'''
+:::* Preferred regimen (3): [[Cefazolin]] 33 mg/kg/dose IV q8h
-::* Preferred regimen: [[Doxycycline]] 100 mg every 12 h IV {{and}} [[ceftriaxone]] 1 g qid IV {{or}} [[cefotaxime]] 2 g tid IV
+:::* Preferred regimen (4): [[Vancomycin]] 15 mg/kg/dose IV q6h
+:::* Preferred regimen (5): [[Clindamycin]] 10–13 mg/kg/dose IV q8h (bacteriostatic; potential cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in MRSA)
+:* 4. '''Clostridium species'''
+::* 4.1 '''Adults'''
+:::* Preferred regimen: [[Clindamycin]] 600–900 mg IV q8h {{and}} [[Penicillin]] 2–4 MU IV q4–6h
+::* 4.2 '''Pediatrics'''
+:::*Preferred regimen: [[Clindamycin]] 10–13 mg/kg/dose IV q8h {{and}} [[Penicillin]] 0.06-0.1 MU/kg/dose IV q6h
+:* 5. '''Aeromonas hydrophila'''
+::* 5.1 '''Adults'''
+:::* Preferred regimen (1): [[Doxycycline]] 100 mg IV q12h {{and}} [[ciprofloxacin]] 500 mg IV q12h
+:::* Preferred regimen (2): [[Doxycycline]] 100 mg IV q12h {{and}} [[ceftriaxone]] 1 to 2 g IV q24h
+::* 5.2 '''Pediatrics'''
+:::* Not recommended for children but may need to use in life-threatening situations
+:* 6. '''Vibrio vulnificus
+::* 6.1 '''Adults'''
+:::* Preferred regimen (1): [[Doxycycline]] 100 mg IV q12h {{and}} [[ceftriaxone]] 1 g IV qid
+:::* Preferred regimen (2): [[Doxycycline]] 100 mg IV q12h {{and}} [[cefotaxime]] 2 g IV tid
-:* '''Vibrio vulnificus, pediatric'''
+::* 6.2 '''Pediatrics'''
-Not recommended for children but may need to use in life-threatening situation
+:::* Not recommended for children but may need to use in life-threatening situation
 ===Pilonidal cyst===
-*Pilonidal cyst<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* Pilonidal cyst<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:*Preferred regimen : A 5-10 day course of antibiotic active against pathogens isolated.
+:* Preferred regimen: After the pathogens isolated, a 5-10 day course of antibiotic is prescribed.
 ===Pyomyositis===
-*Pyomyositis<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Pyomyositis<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:*Preferred regimen : [[nafcillin]] {{or}} [[oxacillin]] 2 gm IV q4h {{or}} [[cefazolin]] 2gm IV q8h (If MSSA)
+:* Preferred regimen (1): [[Nafcillin]]
-:*Alternate regimen : [[vancomycin]] 1gm IV q 12h (If MRSA)
+:* Preferred regimen (2): [[Oxacillin]] 2 g IV q4h
+:* Preferred regimen (3): [[Cefazolin]] 2 g IV q8h (if MSSA)
+:* Alternate regimen: [[Vancomycin]] 1 g IV q12h (if MRSA)
 ===Seborrheic dermatitis===
 * Seborrheic dermatitis<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:* '''Antifungal agents'''
+:* 1. '''Antifungal agents'''
-::* Preferred regimen (1): [[Ketoconazole]] 2% in shampoo, foam, gel, or cream‡ Scalp: twice/wk for clearance, then once/wk or every other wk for maintenance; other areas: from twice daily to twice/wk for clearance, then from twice/wk to once every other wk for maintenance
+::* Preferred regimen (1): [[Ketoconazole]] 2% in shampoo, foam, gel, or cream
-::* Preferred regimen (2): [[Bifonazole]] 1% in shampoo or cream Scalp: 3 times/wk for clearance; other areas: once daily for clearance
+:::* Scalp: Twice/week for clearance {{then}} once/week or every other week for maintenance
-::* Preferred regimen (3): [[Ciclopirox|Ciclopirox olamine]] (also called ciclopirox) 1.0% or 1.5% in shampoo or cream Scalp: twice to 3 times/wk for clearance, then once/wk or every 2 wk for maintenance; other areas: twice daily for clearance, then once daily for maintenance
+:::* Other areas: From bid to twice/week for clearance {{then}} from twice/week to once every other week for maintenance
+::* Preferred regimen (2): [[Bifonazole]] 1% in shampoo or cream
+:::* Scalp: 3 times/week for clearance
+:::* Other areas: qd for clearance
+::* Preferred regimen (3): [[Ciclopirox olamine]] (also called ciclopirox) 1.0% or 1.5% in shampoo or cream
+:::* Scalp: Twice to 3 times/week for clearance {{then}} once/week or every 2 week for maintenance
+:::* Other areas: Twice daily for clearance {{then}} qd for maintenance
-:* '''Corticosteroids'''
+:* 2. '''Corticosteroids'''
-::* Preferred regimen (1): [[Hydrocortisone]] 1% in cream Areas other than scalp: once or twice daily
+::* Preferred regimen (1): [[Hydrocortisone]] 1% in cream areas other than scalp qd or bid
-::* Preferred regimen (2): [[Betamethasone dipropionate]] 0.05% in lotion Scalp and other areas: once or twice daily
+::* Preferred regimen (2): [[Betamethasone dipropionate]] 0.05% in lotion scalp and other areas qd or bid
-::* Preferred regimen (3): [[Clobetasol|Clobetasol 17- butyrate]] 0.05% in cream Areas other than scalp: once or twice daily
+::* Preferred regimen (3): [[Clobetasol|Clobetasol 17- butyrate]] 0.05% in cream areas other than scalp qd or bid
-::* Preferred regimen (4): [[Clobetasol|Clobetasol dipro- pionate]] 0.05% in shampoo Scalp: twice weekly in a short- contact fashion (up to 10 min application, then washing)
+::* Preferred regimen (4): [[Clobetasol|Clobetasol dipro- pionate]] 0.05% in shampoo
-::* Preferred regimen (5): [[Desonide]] 0.05% in lotion Scalp and other areas of skin: twice daily
+:::* Scalp: Twice weekly in a short- contact fashion (up to 10 min application, then washing)
+::* Preferred regimen (5): [[Desonide]] 0.05% lotion bid on scalp and other areas
-:* '''Lithium salts'''
+:* 3. '''Lithium salts'''
-::* Preferred regimen: [[Lithium succinate]] {{and}} [[zinc sulfate]] Ointment containing 8% [[lithium succinate]] plus 0.05% [[zinc sulfate]]
+::* Preferred regimen: [[Lithium succinate]] {{and}} [[Zinc sulfate]] Ointment containing 8% [[Lithium succinate]] {{and}} 0.05% [[Zinc sulfate]]
-::* Preferred regimen: [[Lithium|Lithium gluconate]] 8% in gel Areas other than scalp: twice daily
+::* Preferred regimen: [[Lithium|Lithium gluconate]] 8% in gel bid on areas other than scalp
 ===Skin and soft tissue infection in neutropenic fever===
-*Skin and soft tissue infection in neutropenic fever<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* '''Treatment of skin and soft tissue infection in neutropenic fever'''<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:*Initial episode
+:* 1. '''Initial episode'''
-::*Empiric treatment : [[vancomycin]] {{and}} ([[Carbapenem]] {{or}} [[imipenem]] {{or}} [[meropenem]] {{or}} [[doripenem]] {{or}} [[piperacillin-tazobactam]])
+::* Empiric treatment : [[Vancomycin]] {{and}} ([[Carbapenem]] {{or}} [[Imipenem]] {{or}} [[Meropenem]] {{or}} [[Doripenem]] {{or}} [[Piperacillin-Tazobactam]])
-::*Recurrent or persistent
+:* 2. '''Recurrent or persistent'''
-::*Empiric treatment :
+::* Empiric treatment
-:::* Antibacterial
+:::* 2.1 '''Antibacterial therapy'''
-::::*Preferred treatment : [[Vancomycin]] 30–60 mg/kg/d IV in 2–4 divided doses (Target serum trough concentrations of 15–20 µg/mL in severe infections)
+::::* Preferred regimen (1): [[Vancomycin]] 30–60 mg/kg/day IV in 2–4 divided doses (Target serum trough concentrations of 15–20 µg/mL in severe infections)
-::::*Preferred treatment : [[Daptomycin]] 4–6 mg/kg/d IV (Covers VRE, strains nonsusceptible to vancomycin may be cross-resistant to daptomycin)
+::::* Preferred regimen (2): [[Daptomycin]] 4–6 mg/kg/day IV (Covers VRE, strains nonsusceptible to vancomycin may be cross-resistant to daptomycin)
-::::*Preferred treatment : [[Linezolid]] 600 mg every 12 h IV (100% oral bioavailability; so oral dose same as IV dose. Covers VRE and MRSA)
+::::* Preferred regimen (3): [[Linezolid]] 600 mg q12h IV (100% oral bioavailability; so oral dose same as IV dose. Covers VRE and MRSA)
-::::*Preferred treatment : [[Colistin]] 5 mg/kg load, then 2.5 mg/kg every 12 h IV (Nephrotoxic; does not cover gram-positives or anaerobes, Proteus, Serratia, Burkholderia)
+::::* Preferred regimen (4): [[Colistin]] 5 mg/kg IV loaing dose, {{then}} 2.5 mg/kg q12h IV (Nephrotoxic; does not cover gram-positives or anaerobes, Proteus, Serratia, Burkholderia)
-:::* Antifungal
+:::* 2.2 '''Antifungal therapy'''
-::::*Preferred treatment : [[Fluconazole]] 100–400 mg PO every 24 h {{or}} 800 mg IV loading dose, then 400 mg daily (Candida krusei and Candida glabrata are resistant)
+::::* Preferred regimen (1): [[Fluconazole]] 100–400 mg PO q24h {{or}} [[Fluconazole]] 800 mg IV loading dose, {{then}} 400 mg qd (Candida krusei and Candida glabrata are resistant)
-::::*Preferred treatment : [[Voriconazole]] 400 mg bid × 2 doses PO , then 200 mg every 12 h {{or}} 6 mg/kg IV every 12 h for 2 doses, followed by 4 mg/kg IV every 12 h (Accumulation of cyclodextrin vehicle with IV formulation with renal insufficiency)
+::::* Preferred regimen (2): [[Voriconazole]] 400 mg PO  bid in 2 doses, then 200 mg q12h {{or}} [[Voriconazole]] 6 mg/kg IV q12h for 2 doses, {{then}} 4 mg/kg IV q12h (Accumulation of cyclodextrin vehicle with IV formulation with renal insufficiency)
-::::*Preferred treatment : [[Posaconazole]] 400 mg bid PO with meals (Covers Mucorales)
+::::* Preferred regimen (3): [[Posaconazole]] 400 mg PO bid with meals (Covers Mucorales)
-::::*Preferred treatment : Lipid complex [[amphotericin]] B 5 mg/kg/d IV (Not active against fusaria)
+::::* Preferred regimen (4): Lipid complex [[Amphotericin-B]] 5 mg/kg/day IV (Not active against fusaria)
-::::*Preferred treatment : Liposomal [[amphotericin]] B 3–5 mg/kg/d IV (Not active against fusaria)
+::::* Preferred regimen (5): Liposomal [[Amphotericin-B]] 3–5 mg/kg/day IV (Not active against fusaria)
-:*Culture directed antimicrobial therapy
+:* Culture directed antimicrobial therapy
-::*Candida
+::* Candida
-::*Aspergillus
+::* Aspergillus
-::*Fusarium
+::* Fusarium
-::*Dissemianted HSV or VZV
+::* Dissemianted HSV or VZV
 ===Skin and soft tissue infection in  cellular immunodeficiency===
@@ Line 342: / Line 396: @@
 ===Surgical site infection===
+* '''Surgical site infection treatment'''<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+:* 1. '''Surgery of intestinal or genitourinary tract'''
+::* 1.1 '''Single-drug regimens'''
+:::* Preferred regimen (1): [[Ticarcillin-clavulanate]] 3.1 g IV q6h
+:::* Preferred regimen (2): [[Piperacillin-tazobactam]] 3.375 g IV q6h {{or}} [[Piperacillin-tazobactam]] 4.5 g IV q8h
+:::* Preferred regimen (3): [[Imipenem]]-[[cilastatin]] 500 mg IV q6h
+:::* Preferred regimen (4): [[Meropenem]] 1 g IV q8h
+:::* Preferred regimen (5): [[Ertapenem]] 1 g IV q24h
+::* 1.2 '''Combination regimens'''
+:::* Preferred regimen (1): [[Ceftriaxone]] 1 g IV q24h {{and}} [[metronidazole]] 500 mg IV q8h
+:::* Preferred regimen (2): [[Ciprofloxacin]] 400 mg IV q12h (or [[Ciprofloxacin]] 750 mg IV PO q12h) {{and}} [[metronidazole]] 500 mg IV q8h
+:::* Preferred regimen (3): [[Levofloxacin]] 750 mg IV q24h {{and}} [[metronidazole]] 500 mg IV q8h
+:::* Preferred regimen (4): [[Ampicillin-sulbactam]] 3 g IV q6h {{and}} [[gentamicin]] ({{or}} [[tobramycin]] 5 mg/kg IV q24h)
-* Surgical site infection<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+:* 2. '''Surgery of trunk or extremity away from axilla or perineum'''
+::* Preferred regimen (1): [[Oxacillin]] or [[nafcillin]] 2 g IV q6h
+::* Preferred regimen (2): [[Cefazolin]] 0.5–1 g IV q8h
+::* Preferred regimen (3): [[Cephalexin]] 500 mg PO q6h
+::* Preferred regimen (4): [[SMX-TMP]] 160–800 mg PO q6h
+::* Preferred regimen (5): [[Vancomycin]] 15 mg/kg IV q12h
-:* '''Surgery of intestinal or genitourinary tract'''
+:* 3. '''Surgery of axilla or perineum'''
-::* Single-drug regimens
+::* Preferred regimen (1): [[Metronidazole]] 500 mg IV q8h {{and}} [[Ciprofloxacin]] 400 mg IV q12h ({{or}} [[Ciprofloxacin]] 750 mg PO q12h)
-:::* Preferred regimen (1): [[Ticarcillin-clavulanate]] 3.1 g every 6 h IV
+::* Preferred regimen (2): [[Metronidazole]] 500 mg IV q8h {{and}} [[Levofloxacin]] 750 mg IV/PO q24h
-:::* Preferred regimen (2): [[Piperacillin-tazobactam]] 3.375 g every 6 h {{or}} 4.5 g every 8 h IV
-:::* Preferred regimen (3): [[Imipenem]]-[[cilastatin]] 500 mg every 6 h IV
-:::* Preferred regimen (4): [[Meropenem]] 1 g every 8 h IV
-:::* Preferred regimen (5): [[Ertapenem]] 1 g every 24 h IV
-::* Combination regimens
-:::* Preferred regimen (1): [[Ceftriaxone]] 1 g every 24 h {{and}} [[metronidazole]] 500 mg every 8 h
-:::* Preferred regimen (2): IV [[Ciprofloxacin]] 400 mg IV every 12 h or 750 mg po every 12 h {{and}} [[metronidazole]] 500 mg every 8 h
-:::* Preferred regimen (3): IV [[Levofloxacin]] 750 mg IV every 24 h {{and}} [[metronidazole]] 500 mg every 8 h
-:::* Preferred regimen (4): IV [[Ampicillin-sulbactam]] 3 g every 6 h {{and}} [[gentamicin]] {{or}} [[tobramycin]] 5 mg/kg every 24 h IV
-:* '''Surgery of trunk or extremity away from axilla or perineum'''
+::* Preferred regimen (3): [[Metronidazole]] 500 mg IV q8h {{and}} [[Ceftriaxone]] 1 g q24h
-::* Preferred regimen (1): [[Oxacillin]] or [[nafcillin]] 2 g every 6 h IV
-::* Preferred regimen (2): [[Cefazolin]] 0.5–1 g every 8 h IV
-::* Preferred regimen (3): [[Cephalexin]] 500 mg every 6 h po
-::* Preferred regimen (4): [[SMX-TMP]] 160–800 mg po every 6 h
-::* Preferred regimen (5): [[Vancomycin]] 15 mg/kg every 12 h IV
-:* '''Surgery of axilla or perineum'''
-::* Preferred regimen: [[Metronidazole]] 500 mg every 8 h IV {{and}} ([[Ciprofloxacin]] 400 mg IV every 12 h {{or}} [[Ciprofloxacin]] 750 mg po every 12 h {{or}} [[Levofloxacin]] 750 mg every 24 h IV/PO {{or}} [[Ceftriaxone]] 1 g every 24 h)
 ===Tularemia===
-*'''Tularemia'''<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* '''Tularemia treatment'''<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:* Preferred regimen (1): [[Streptomycin]] 15 mg/kg every 12 hours IM {{or}} [[Gentamicin]] 1.5 mg/kg every 8 hours IV
+:* Preferred regimen (1): [[Streptomycin]] 15 mg/kg IM q12h {{or}} [[Gentamicin]] 1.5 mg/kg IV q8h
 :* Preferred regimen (2): [[Tetracycline]] 500 mg qid {{or}} [[doxycycline]] 100 mg bid PO (for mild cases)
-===Vascular insufficieny ulcer===
+=== Ulcerated skin: Venous/Arterial Insufficiency; Pressure with Secondary Infection (Infected Decubiti)===
-*Vascular insufficieny ulcer<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* Ulcerated skin: venous/arterial insufficiency; pressure with secondary infection (infected decubiti) treatment<ref name="pmid24126647">{{cite journal| author=Greer N, Foman NA, MacDonald R, Dorrian J, Fitzgerald P, Rutks I et al.| title=Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. | journal=Ann Intern Med | year= 2013 | volume= 159 | issue= 8 | pages= 532-42 | pmid=24126647 | doi=10.7326/0003-4819-159-8-201310150-00006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24126647  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24347199 Review in: Evid Based Med. 2014 Jun;19(3):91] </ref>
+:* Preferred regimen (1): [[Imipenem]] 0.5 g IV q6h ({{or}} [[Meropenem]] 1 g IV q24h {{or}} [[Doripenem]] 500 mg IV q8h)
-:* Preferred regimen : [[Imipenem]] 0.5 gm IV q6hr {{or}} [[meropenem]] 1gm IV q24 hr {{or}} [[doripenem]] 500mg IV q8hr {{or}} [[ticarcillin-clavulanate]] 3.1gm IV q8hr {{or}} [[piperacillin-tazobactam]] 3.375gm IV q6hr {{or}} [[ertapenem]] 1gm IV q24hr
+:* Preferred regimen (2): [[Ticarcillin-Clavulanate]] 3.1 g IV q8h
+:* Preferred regimen (3): [[Piperacillin-Tazobactam]] 3.375 g IV q6h
+:* Preferred regimen (4): [[Ertapenem]] 1 g IV q24h
+:* Alternative regimen (1): [[Ciprofloxacin]] 500 mg PO bid {{or}} [[Levofloxacin]] PO 500 mg qd {{and}} [[Metronidazole]] 500 mg PO qid
+:* Alternative regimen (2): [[Cefepime]] 2 g IV q12h {{or}} [[Ceftazidime]] 2 g IV q8h {{and}} [[Metronidazole]] 500 mg PO qid
+:* Note (1): If gram positive cocci on gram stain add [[Vancomycin]].
+:* Note (2): If the ulcer is inflamed, treat with parenteral antibiotics with no topical treatment.
+:* Note (3): If the ulcer is not clinically inflamed, consider debridement, removal of foreign body, reduce the pressure for weight bearing limbs and leg elevation.
+:* Note (4): If not inflamed, healing improved on air bed, protein supplement, radiant heat and electric stimulation.
+:* Note (5): Avoid [[chlorhexidine]] and [[povidone iodine]] as it may harm the granulation tissue.
 ===Vibrio infection===
-*Vibrio infection<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+* Vibrio infection<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
+:* '''Vibrio vulnificus in adults'''
-:* '''Vibrio vulnificus, adult'''
+::* Preferred regimen: [[Doxycycline]] 100 mg IV q12h {{and}} [[ceftriaxone]] 1 g IV qid  {{or}} [[cefotaxime]] 2 g IV tid
-::* Preferred regimen: [[Doxycycline]] 100 mg every 12 h IV {{and}} [[ceftriaxone]] 1 g qid IV {{or}} [[cefotaxime]] 2 g tid IV
+::* Note: Antibiotic treatment is not recommended for children but may need to use in life-threatening situation
-:*'''Vibrio vulnificus, pediatric'''
-Not recommended for children but may need to use in life-threatening situation
 ===Wound infection===
-*Wound infection<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+* '''Wound infection'''<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Mild to moderate
+:* 1. '''Mild to moderate'''
-::* Preferred regimen : [[TMP-SMX]] double strength 1-2 tabs PO bid {{or}} [[clindamycin]] 300-450 mg PO tid
+::* Preferred regimen (1): [[TMP-SMX]]-DS double strength 1-2 tabs PO bid
-::* Alternate regimen : [[Minocycline]] 100mg PO bid {{or}} [[linezolid]] 600mg PO bid
+::* Preferred regimen (2): [[Clindamycin]] 300-450 mg PO tid
-:* Febrile with sepsis
+::* Alternative regimen (1): [[Minocycline]] 100 mg PO bid
-::* Preferred regimen : [[Ticarcillin-clavulanate]] 3.1 gm IV q4-6hr {{or}} [[piperacillin-tazobactam]] 3.375 gm q 6hr {{or}} [[doripenem]]500 mg IV q 8hr {{or}} [[imipenem]] {{or}} [[meropenem]] {{or}} [[ertapenem]] 1gm IV q24 hr) {{and}} [[vancomycin]] 1gm IV q12h
+::* Alternative regimen (2): [[Linezolid]] 600 mg PO bid
-::* Alternate regimen : [[vancomycin]] 1gm IV q12h {{or}} [[daptomycin]] 6mg/kg iv q24h {{or}} [[ceftaroline]] 600mg IV q12h {{or}} [[telavancin]] 10mg/kg IV q24h {{and}} ([[ciprofloxacin]] {{or}} [[levofloxacin]] 750mg IV q24h)
+:* 2. '''Febrile with sepsis'''
+::* Preferred regimen (1): [[Ticarcillin-clavulanate]] 3.1 g IV q4-6h ({{or}} [[Piperacillin-Tazobactam]] 3.375 g q6h) {{and}} [[Vancomycin]] 1g IV q12h
+::* Preferred regimen (2): [[Doripenem]] 500 mg IV q 8hr ({{or}} [[Imipenem]] {{or}} [[Meropenem]] {{or}} [[Ertapenem]] 1g IV q24h) {{and}} [[Vancomycin]] 1g IV q12h
+::* Alternative regimen (1): [[Vancomycin]] 1 g IV q12h ({{or}} [[Daptomycin]] 6 mg/kg IV q24h) {{and}} [[Ciprofloxacin]] 750 mg IV q24h ({{or}} [[Levofloxacin]] 750 mg IV q24h)
+::* Alternative regimen (2): [[Ceftaroline]] 600 mg IV q12h  {{and}} [[Ciprofloxacin]] 750 mg IV q24h ({{or}} [[Levofloxacin]] 750 mg IV q24h)
+::* Alternative regimen (3): [[Telavancin]] 10 mg/kg IV q24h {{and}} [[Ciprofloxacin]] 750 mg IV q24h ({{or}} [[Levofloxacin]] 750 mg IV q24h)
 ===Yaws===
 *Yaws<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530  }} </ref>
-:*  Preferred regimen (1): [[Phenoxymethylpenicillin]] 7–10 d; 12.5 mg/kg q6h (maximum dose, 300 mg q6h)
+:*  Preferred regimen (1): [[Phenoxymethylpenicillin]] 12.5 mg/kg q6h 7-10days (maximum dose, 300 mg q6h)
-:*  Preferred regimen (2): [[Tetracyclines]] 15 d; [[tetracycline]] 500 mg q6h or [[doxycycline]] 100 mg q12h Alternative agents for the treatment of yaws in nonpregnant adults
+:*  Preferred regimen (2): [[Tetracyclines]] 500 mg q6h 15 days or [[doxycycline]] 100 mg q12h (alternative agents for the treatment of yaws in nonpregnant adults)
-:*  Preferred regimen (3): [[Erythromycin]] 15 d; 8–10 mg/kg q6h
+:*  Preferred regimen (3): [[Erythromycin]] 8–10 mg/kg 15 days q6h
-:*  Preferred regimen (4): [[Azithromycin]] Single-dose; 30 mg/kg (maximum dose 2 g)
+:*  Preferred regimen (4): [[Azithromycin]] 30 mg/kg single-dose (maximum dose 2 g)
 ==References==
 {{reflist|2}}